Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial

European Psychiatry

Volumn 22, Issue 3, 2007, Pages 195-202

  Kudla, Duerten ^a   Lambert, Martin ^a   Domin, Sabine ^a   Kasper, Siegfried ^b   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotics; Quality of life; Schizophrenia; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; ZIPRASIDONE;

ADULT; AGED; AGITATION; ARTICLE; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERKINESIA; INSOMNIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT FORM 12; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION; WELLBEING;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRIA; BLOOD GLUCOSE; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; LIPIDS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 33947729686     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2006.06.004     Document Type: Article

References (32)

1. Addington D.E., Pantelis C., Dineen M., Benattia I., and Romano S.J. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 65 (2004) 1624-1633
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2004. second edition (2004), APA, Arlington, VA 249-440
3. Arato M., O'Connor R., Meltzer H.Y., and ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17 (2002) 207-215
4. Bagnall A., Lewis R.A., and Leitner M.L. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 4 (2000) CD001945
5. Brook S., Walden J., Benattia I., Siu C.O., and Romano S.J. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology 178 (2005) 514-523
6. Citrome L., Volavka J., Czobor P., Brook S., Loebel A., and Mandel F.S. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 67 (2006) 638-642
7. Clark G. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
8. Franciosi L.P., Kasper S., Garber A.J., Johnson D.L., Krauss R.M., Marder S.R., et al. Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. J Clin Psychiatry 66 (2005) 790-798
9. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338 (1976), National Institute of Mental Health, Rockville, MD p 218-222
10. Harrigan E.P., Miceli J.J., Anziano R., Watsky E., Reeves K.R., Cutler N.R., et al. A randomized evaluation of the effects of six antipsychotic agents on QTc in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24 (2004) 62-69
11. Harvey P.D., Meltzer H., Simpson G.M., Potkin S.G., Loebel A., Siu C., et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66 (2004) 101-113
12. Harvey P.D., and Bowie C.R. Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. Expert Opin Pharmacother 6 (2005) 337-346
13. Henderson D.C. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 66 Suppl 6 (2005) 11-20
14. Joyce A.T., Harrison D.J., Loebel A.D., Carter C.T., and Ollendorf D.A. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr Res 83 (2006) 285-292
15. Lambert M., Conus P., Schimmelmann B., Eide P., Ward J., Yuen H.P., et al. Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. Pharmacopsychiatry 38 (2005) 206-213
16. Lambert M, Eich FX, Schacht M, Naber D, Linden M, Schimmelmann BG. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scand, in press, doi:10.1111/j.1600-0447.2006.00862x.
17. Levy W.O., Robichaux-Keene N.R., and Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 10 (2004) 227-232
18. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
19. Loebel A., Siu C., and Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 9 (2004) 357-364
20. McGorry P.D., Killackey E., Lambert T., and Lambert M. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 39 (2005) 1-30
21. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161 (2004) 818-825
22. Mullins C.D., Shaya F.T., Zito J.M., Obeidat N., Naradzay J., and Harrison D.J. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr Res 83 (2006) 277-284
23. Naber D., Moritz S., Lambert M., Pajonk F., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50 (2001) 79-88
24. Nemeroff C.B., Lieberman J.A., Weiden P.J., Harvey P.D., Newcomer J.W., Schatzberg A.F., et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 10 (2005) 1-20
25. Olie J.P., Spina E., Murray S., and Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 21 (2006) 143-151
26. Overall J.E., and Gorham D.R. BPRS. Brief Psychiatric Rating Scale. In: Guy W., and Bonato R.R. (Eds). EDCEU assessment battery. Revised ed. (1976), EDCEU, Rockville, MD 157-169
27. Pajonk F.G. Clinical trial design in schizophrenia: implications for clinical decisions. Curr Opin Psychiatry 18 (2005) 692-699
28. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
29. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., and Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161 (2004) 1837-1847
30. Ware Jr. J., Kosinski M., and Keller S.D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34 (1996) 220-233
31. Weiden P.J., Simpson G.M., Potkin S.G., and O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64 (2003) 580-588
32. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 65 Suppl 18 (2004) 13-26